ruxolitinib,pelabresib
incyte,novartis,morphosys
['manifest study', 'morphosys']
at #eha2023, we re presenting preliminary results from one arm of the phase 2 manifest study, which explored our investigational bet inhibitor in patients with high-risk essential thrombocythemia. learn more: 
Global commercial-stage biopharmaceutical company driven by our mission: More life for people with cancer. https://t.co/IMbjQ1Ym1Z